A Phase 1 Study Evaluating The Safety And Efficacy Of KITE-753, Autologous Anticd19/CD20 CAR T-Cell Therapies, In Patients With Relapsed And/Or Refractory B-Cell Acute Lymphoblastic Leukemia

Study Summary

The goal of this clinical research study is to find the recommended dose of KITE-753 in patients with relapsed/refractory B-cell ALL. The safety of KITE-753 will also be studied.

Interventions

Study Locations

Facility	City	State	Country
UT MD Anderson	Houston	Texas	United States

Official Trial Information

View on ClinicalTrials.gov